Glaukos Corporation (GKOS)

NYSE: GKOS · IEX Real-Time Price · USD
48.04
-0.14 (-0.29%)
Jan 27, 2023, 4:00 PM EST - Market closed
-0.29%
Market Cap 2.29B
Revenue (ttm) 284.88M
Net Income (ttm) -89.61M
Shares Out 47.70M
EPS (ttm) -1.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 325,546
Open 48.06
Previous Close 48.18
Day's Range 47.15 - 48.29
52-Week Range 33.33 - 64.49
Beta 1.20
Analysts Buy
Price Target 58.55 (+21.88%)
Earnings Date Feb 20, 2023

About GKOS

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; a... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Thomas Burns
Employees 727
Stock Exchange NYSE
Ticker Symbol GKOS
Full Company Profile

Financial Performance

In 2021, Glaukos's revenue was $294.01 million, an increase of 30.70% compared to the previous year's $224.96 million. Losses were -$49.59 million, -58.79% less than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for GKOS stock is "Buy." The 12-month stock price forecast is $58.55, which is an increase of 21.88% from the latest price.

Price Target
$58.55
(21.88% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

2 weeks ago - Business Wire

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

2 weeks ago - Business Wire

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

3 weeks ago - Zacks Investment Research

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

1 month ago - Business Wire

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.

1 month ago - Zacks Investment Research

Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

Here's Why Glaukos (GKOS) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Glaukos (GKOS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisio...

2 months ago - Zacks Investment Research

Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

3 months ago - Zacks Investment Research

Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 15.09% and 4.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Glaukos Corporation Announces Third Quarter 2022 Financial Results

ALISO VIEJO, Calif.

3 months ago - Business Wire

4 MedTech Stocks Set to Outpace Q3 Earnings Estimates

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Other symbols: MASINVRO
3 months ago - Zacks Investment Research

Glaukos (GKOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

4 months ago - Business Wire

Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR

Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.

5 months ago - Zacks Investment Research

(GKOS) – What's Going On With Glaukos Stock?

Glaukos Corp (NYSE: GKOS) shares are trading higher by 1.87% to $49.00 Wednesday morning after the company announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved...

5 months ago - Benzinga

Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

5 months ago - Business Wire

Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

5 months ago - Business Wire

Why Is Glaukos (GKOS) Down 8.7% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation

BOSTON , Aug. 29, 2022 /PRNewswire/ -- – Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with development...

5 months ago - PRNewsWire

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal di...

5 months ago - Business Wire

Glaukos Licenses Iveena's Investigational Keratoconus Therapy

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a...

5 months ago - Business Wire

Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition

Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.

5 months ago - Zacks Investment Research

Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat

Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.

6 months ago - Zacks Investment Research